Please assess the completion status of the following clinical trial:

Trial Title: Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI: 30.0-34.99 kg / m2.~* Diagnosis of IGT (OGTT Values between 140mg / dl and 199mg / dl.~* Written informed consent.~* Body weight stable over the last 3 months.~* Women in follicular phase of the menstrual cycle (days 3 to 8 of the cycle) at the time of laboratory tests.~* Women who are not contemplated get pregnant within the next 6 months.~Exclusion Criteria:~* Women pregnant or breastfeeding.~* Physical or mental disability that makes it impossible to perform the intervention.~* Diagnosis of Hypertension or heart failure.~* Smokers.~* Untreated thyroid disease.~* Consumption of oral agents or other medications or supplements with proven properties that modify the behavior of glucose and lipids (oral hypoglycemic agents, insulin, lipid-lowering).~* Diagnosis of liver disease or elevation twice of the upper normal value of liver enzymes.~* Diagnosis of renal disease or creatinine \> 1.5 mg / dl.~* Diagnosis of Type 2 Diabetes Mellitus (T2DM) Fasting glucose ≥ 126 mg / dL and/or OGTT ≥ 200 mg / dL and/or A1C ≥ 6.5%.~* Total Cholesterol ≥ 280 mg/dL.~* Triglycerids ≥ 300 mg/dL.~* Known allergy to calcined magnesia or Chorogenic acid.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
- Chlorogenic acid (Type: EXPERIMENTAL): 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).